Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery

O’Riordan, J M; Byrne, Patrick J.; Ravi, Narayanasamy; Keeling, P. W. N.; Reynolds, John V.

doi:10.1016/j.amjsurg.2003.10.025

Cited by 80 publications

(58 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six uncontrolled studies have evaluated the risk of neoplastic progression after antireflux surgery without PPI treatment [55,56,73,74,75,76]. The results of these studies are shown in table 2.…”

Section: Development and Progression Of Dysplasiamentioning

confidence: 93%

Role of Acid Suppression in the Development and Progression of Dysplasia in Patients with Barrett’s Esophagus

Kastelein

Spaander²,

Biermann³

et al. 2011

Dig Dis

View full text Add to dashboard Cite

Barrett’s esophagus (BE) usually develops in patients with gastroesophageal reflux disease and therefore it has been suggested that esophageal acid exposure plays an import role in the initiation of BE and its progression towards esophageal adenocarcinoma (EAC). The mechanisms whereby acid exposure causes BE are not completely revealed and the potential role of esophageal acid exposure in carcinogenesis is unclear as well. Since acid exposure is thought to play an important role in the progression of BE, therapies aimed at preventing the development of EAC have primarily focused on pharmacological and surgical acid suppression. In clinical practice, acid suppression is effective in relieving reflux symptoms and decreases esophageal acid exposure in most patients. However, in some individuals, pathological acid exposure persists and these patients continue to be at risk for developing dysplasia or EAC. To date, published trials suggest that acid suppression is able to prevent the development and progression of dysplasia in patients with BE, but definite and compelling proof is still lacking. This article reviews the mechanisms of acid-induced carcinogenesis in BE and the role of acid suppression in the prevention of neoplastic progression.

show abstract

Section: Development and Progression Of Dysplasiamentioning

confidence: 93%

Role of Acid Suppression in the Development and Progression of Dysplasia in Patients with Barrett’s Esophagus

Kastelein

Spaander²,

Biermann³

et al. 2011

Dig Dis

View full text Add to dashboard Cite

show abstract

“…The success of acid-suppressive therapy in the management of GORD has lessened the need for surgical intervention [80]. However, studies have indicated that anti-reflux surgery is an effective approach, with overall outcomes equal to and possibly superior to those achieved with medication [81,82].…”

Section: Effects Of Treatmentmentioning

confidence: 99%

Barrett's Oesophagus

2012

Morson and Dawson's Gastrointestinal Pathology

View full text Add to dashboard Cite

“…La cirugía antirrefl ujo en EB también logra la regresión de la metaplasia intestinal, pero no en las proporciones a las obtenidas por nuestro estudio 19,20 . Otros mecanismos fi siopatológicos que explicarían nuestros resultados y las diferencias con la cirugía antirrefl ujo, es que el bypass gástrico es una técnica signifi cativa para la reducción de peso.…”

Section: Descripción De Nuevos Mecanismos Fi Siopatológicosunclassified

Efectos del bypass gástrico en el esófago de Barrett de pacientes con obesidad mórbida

et al. 2012

Rev Chil Cir

View full text Add to dashboard Cite

Effects of gastric bypass for morbid obesity on Barrett esophagusBackground: Besides the weight reducing effects of gastric bypass, it is also a good antirefl ux procedure since there is no acid production by the gastric pouch and there is no duodenal refl ux due to the presence of a Roux en Y. Aim: To describe the effect of gastric bypass on Barrett esophagus among patients with morbid obesity. Material and Methods: Among 896 patients subjected to gastric bypass, 14 patient with a Barrett esophagus diagnosed with endoscopy and biopsy, were followed. A new endoscopy was performed one to 30 months after the surgical procedure. Results: Short (< = 30 mm) and long segment (> = 31 mm) Barrett esophagi were present in eight and six patients, respectively. Gastroesophageal refl ux symptoms relieved in 70% of these cases in a mean lapse of 6.5 months. There was regression from intestinal metaplasia to cardial mucosa in six patients (75%) with short-segment, and in one patient (16%) with long-segment Barrett esophagus. Conclusions: Gastric bypass in patients with morbid obesity and Barrett esophagus is a very good antirefl ux operation. This was proved by the disappearance of symptoms in almost all patients and by the regression of the intestinal metaplasia which is time and length dependent.

show abstract

Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery

Cited by 80 publications

References 26 publications

Role of Acid Suppression in the Development and Progression of Dysplasia in Patients with Barrett’s Esophagus

Role of Acid Suppression in the Development and Progression of Dysplasia in Patients with Barrett’s Esophagus

Barrett's Oesophagus

Efectos del bypass gástrico en el esófago de Barrett de pacientes con obesidad mórbida

Contact Info

Product

Resources

About